Phosphodiesterase-4 (PDE4), which metabolizes the second messenger cyclic adenosine
monophosphate (cAMP), has 4 isozymes: PDE4A, PDE4B, PDE4C, and PDE4D. PDE4B …

Phosphodiesterases are enzymes that inactivate the intracellular second messengers 3′,
5′-cyclic adenosine-monophosphate and/or cyclic guanosine-monophosphate. Of all 11 …

The enzyme phosphodiesterase 2A (PF-05270430) is a potential target for development of
novel therapeutic agents for the treatment of cognitive impairments. The goal of the present …

Phosphodiesterase (PDE) 10A is an enzyme involved in the regulation of cyclic adenosine
monophosphate and cyclic guanosine monophosphate and is highly expressed in medium …

Abstract Introduction Phosphodiesterase 10A (PDE10A) is a dual-substrate PDE that
hydrolyzes both cAMP and cGMP and is selectively expressed in striatal medium spiny …

Phosphodiesterase-4D (PDE4D) has emerged as a significant target for treating
neuropsychiatric disorders, but no PET radioligand currently exists for robustly quantifying …

Phosphodiesterase 10A (PDE10A) plays a key role in the regulation of brain striatal
signaling, and several pharmaceutical companies currently investigate PDE10A inhibitors in …

Four novel phosphodiesterase 10A (PDE10A) PET tracers have been synthesized,
characterized in preclinical studies, and compared with the previously reported 11C-MP-10 …

ABSTRACT Phosphodiesterase 10A (PDE10A) is considered to be a key target for the
treatment of several neuropsychiatric diseases. The characteristics of [11C] T‐773, a novel …

This was a first-in-human study of the novel phosphodiesterase-2A (PDE2A) PET ligand 18F-
PF-05270430. The primary goals were to determine the appropriate tracer kinetic model to …